CAPRICOR THERAPEUTICS, INC. - 8-K Filing

Capricor Therapeutics reports Q3 2026 net loss of $42.7 million and announces PDUFA date of November 22, 2026, for Deramiocel BLA. (Items: 2.02 of this Current Report on Form 8-K and Exhibit 99)

SEC EDGAR ·

Tickers: $CAPR

Read the full article at SEC EDGAR

More Regulatory news